News

Novo Nordisk Shares Jump as Eli Lilly's Weight-Loss Pill Data Disappoints
(Reuters) -Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...
Novo Nordisk AS (NVO) Q2 2025 Earnings Call Highlights: Robust Growth in Obesity Care and ...
Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic ...
Novo Nordisk's Wegovy, Mounjaro sales in India double on month in July
Sales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, ...
Investor's Business Daily on MSN20h
Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy
Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...
Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Fierce Pharma1d
Novo Nordisk faces investor lawsuit over 'false and misleading' semaglutide sales projections
Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...
pharmaphorum1d
Novo Nordisk weakens again on interim results readout
Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...
Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025
Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...